Latest Headlines

Latest Headlines

Kleiner Perkins' Auxogyn gets $34M to better identify an IVF embryo's odds

Last June, Auxogyn's Eeva System was the first to be cleared by FDA to aid in IVF embryo selection in combination with traditional morphology. Now the startup has raised $34.3 million, out of a planned $41 million, financing round to start commercializing this test, according to an SEC filing.

FDA approves Auxogyn embryo test for IVF procedures

The FDA gave de novo approval to Menlo Park-based Auxogyn's Eeva System, a fertility-enhancing diagnostic test currently available in Europe and Canada.  

Merck KGaA signs on to sell Auxogyn's IVF test

Germany's Merck KGaA signed a licensing agreement with Menlo Park, CA-based Auxogyn to sell its fertility-enhancing diagnostic test in Europe and Canada with an option to extend the agreement to other countries.

Auxogyn reels in $18M to fuel IVF/embryo viability test

Auxogyn has reeled in $18 million in Series B funding to help bring its diagnostic test to evaluate embryo viability during in vitro fertilization to the regulatory finish line in a big advance for the field.

Kleiner Perkins to back early-stage biotechs with $525M fund

Kleiner Perkins Caulfield & Byers has closed the books on a new $525 million fund. And a chunk of that treasure is earmarked for early-stage life science companies.